Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Leuk Lymphoma. 2021 Jul;62(7):1711-1720. doi: 10.1080/10428194.2021.1885655. Epub 2021 Feb 24.
Multiple myeloma (MM) immunogenomics studies related to T-cell characterizations and involving large patient sets have been lacking, particularly in comparison to solid tumor types. Thus, we evaluated (i) HLA alleles, and (ii) T-Cell Receptor (TCR) V- and J-gene segment, HLA allele combinations, based on TCR recombinations in blood samples, for their potential associations with overall survival distinctions among an MM cohort. Two HLA alleles, and seven TCR V- or J-gene segment, HLA allele combinations were found to be associated with distinct overall survival rates. For examples, HLA-C08:02, and the TRAV19, HLA-C07:01 combination, were found to be associated with negative outcomes. In addition, anti-cytomegalovirus immune receptor sequences, from blood samples, were found to be associated with a positive outcome ( = 0.012, = 278). These data, and other related immunogenomics data, indicate a potential opportunity to use personal immunogenetics parameters as guides to prognosis and therapies.
多发性骨髓瘤（MM）免疫基因组学研究与 T 细胞特征有关，并涉及大量患者群体，特别是与实体肿瘤类型相比。因此，我们评估了（i）HLA 等位基因，和（ii）T 细胞受体（TCR）V-和 J-基因片段，基于血液样本中的 TCR 重组的 HLA 等位基因组合，它们与 MM 队列中整体生存率的差异的潜在关联。发现两个 HLA 等位基因和七个 TCR V 或 J-基因片段，HLA 等位基因组合与不同的总生存率相关。例如，HLA-C08:02 和 TRAV19、HLA-C07:01 组合被发现与不良预后相关。此外，来自血液样本的抗巨细胞病毒免疫受体序列被发现与良好的预后相关（=0.012，=278）。这些数据和其他相关免疫基因组学数据表明，有机会利用个人免疫遗传学参数作为预后和治疗的指南。
